New Jersey
Celltrion USA plans to acquire and expand Eli Lilly and Co.’s biopharmaceutical plant. in Branchburg. The scope of the estimated $630 million project is being developed, but could include construction and modification of the building space; modification of production lines; and the purchase and installation of automation, storage, handling, formulation, filling and packaging equipment and systems. The expansion will increase the production capacity of pharmaceutical substances and products to 135,000 liters per year. Plant acquisition is expected by the end of 2025. Approximately 50% of the production lines will continue to produce Eli Lilly biologics under contract. Celltrion expects to begin production of its own line of antibody-based biologics for autoimmune and cancer therapies at the site in 2027. Celltrion USA, One Evertrust Plaza, Suite 1207, Jersey City, NJ 07302. IR#NJ250905
virginia
AstraZeneca plans to build a pharmaceutical ingredient and pharmaceutical product manufacturing plant on a 462-acre site in Albemarle County. The scope of the project includes the construction of multiple buildings with clean rooms; and purchase and installation of stainless steel tanks and piping, bioreactors, fume hoods and wet lab, filtration, testing, sterilization, filling, finishing, labeling, packaging and cold storage equipment. A construction schedule is being developed; the project is expected to become operational in 2029 or 2030. The plant will be used to produce small molecules, peptides, oligonucleotides and antibody drug conjugates to produce oral pharmaceuticals for weight and metabolism control, small molecule combination products and oncology indication therapies. AstraZeneca, 1 Medimmune Way, Gaithersburg, MD 20878. IR#VA251001
Wyoming
BWX Technologies Inc. plans to build a tristructural isotropic nuclear particle fuel production facility at Gillette. The scope of the project includes the construction of construction spaces and equipment foundations; as well as the purchase and installation of thermal activation reactors, and equipment and systems for dissolution, mixing, cooling, dispersion, collection, cleaning, rinsing, fluidized bed chemical vapor deposition, isostatic pressing, pelletizing, coating and coating. BWX estimates that construction will begin in the fourth quarter of 2026. BWX Technologies, Inc. Nuclear Operations Group, 800 Main St., Lynchburg, VA 24504. IR#WY251001
